The Japan immunoassay market, valued at USD 1.52 billion in 2024 and expected to grow at a CAGR of 5.5% through 2034, is undergoing a structural evolution driven by innovation in product segmentation and shifting clinical demands. Growth is increasingly concentrated in high-performance assay categories such as chemiluminescence immunoassays (CLIA), enzyme-linked immunosorbent assays (ELISA),...
0 Commentarios
0 Acciones
118 Views
0 Vista previa
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek